North America Persistent Corneal Epithelial Defects Treatment Market – Industry Trends and Forecast to 2029

North America Persistent Corneal Epithelial Defects Treatment Market Analysis and Size

North America persistent corneal epithelial defects treatment market is expected to witness significant growth during the forecast period. Although numerous therapies exist and a growing number of novel approaches are evolving, treatment of this disease can still be quite challenging. It is necessary to treat the underlying causative condition, which includes infection, limbal stem cell deficiency, or diabetes, to facilitate wound healing. The introduction of the latest technology development which offers various therapies for treating various complications caused by the disorder and the rise in incidence of dry eye syndrome boost market growth.

Data Bridge Market Research analyses a growth rate in the North America persistent corneal epithelial defects treatment market in the forecast period 2022-2029. The market was valued at USD 98.8 million in 2021. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

North America Persistent Corneal Epithelial Defects Treatment Market Scope and Segmentation

Market Definition

Persistent Corneal Epithelial Defects (PCED/ PED) are mainly characterized by the failure of rapid re-epithelialization and closure within the range of 10-14 days after a corneal injury, combined with standard supportive treatment. This corneal condition results in the disturbance of the corneal surface and the exposed eyes are vulnerable to stromal ulceration, scarring, and infections.

Persistent Corneal Epithelial Defects Treatment Market Dynamics

Drivers

• Increased Partnerships and Collaborations

The rising partnerships and collaborations between several companies boost the market's growth. For instance, in October 2017, Bio-Tissue entered a strategic agreement with Optima Pharmazeutische GmbH, a pharmaceutical company that offers otorhinolaryngology, ophthalmology, and pneumology products. This agreement helps the company to distribute its Natural Ocular Cleanser in Germany. Thus, all these collaborations boost the growth of the market.

• Higher Demand of Hospitals

The rising demand of hospitals increase the market growth rapidly. Most chronic disease diagnostics are majorly carried out in hospitals as they are very complex and it requires technologically advanced products and thus this is driving the market for hospital/clinical laboratories.

Opportunities

• Rise in Eye Surgeries and Contact Lenses

Increasing cases of eye surgeries and the higher usage of contact lenses is anticipated to boost the market growth. For instance, in 2019, Cindy Tromans published a study on “Therapeutic Contact Lenses”. The study expected that a persistent epithelial defect (PED) can have numerous different etiologies that includes viral or fungal corneal, bacterial infections PED can occur after thermal or chemical burns that leads to slow healing after surgery. Development of novel therapeutics will boost the market and create new opportunities for the growth.

• Increasing Demand of Treatment Types

Lubricant eye drops are the first line treatment for the PCED treatment, but are generally insufficient to treat PCED. Oxervate is one of the most effective treatment methods for persistent corneal epithelial defects treatment was launched in January 2019, so the acceptability is very low for this product. and the pharmaceutical product are more costly compared to device such as Oxervate costs USD 47,200, whereas punctal plug costs approximately USD 27 and bandage contact lens cost about USD 57. Thus, increasing demand for the treatmnet types boost the market's growth.

Restraints/Challenges

• Lack of skilled professionals

The lack of qualified personnel who cannot treat the patients with appropriate treatments could curb the growth of the North America persistent corneal epithelial defects treatment market over a forecast period.

• High Cost

The huge expenditure required for setting up these techniques hamper the market growth. Several market players make huge investment in installing new and advanced machines to faster the process and in return the cost is increased.

This North America persistent corneal epithelial defects treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the North America persistent corneal epithelial defects treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

North America Persistent Corneal Epithelial Defects Treatment Market

The North America persistent corneal epithelial defects treatment market is segmented on the basis of clinical causes, type, end-user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Clinical Causes

• Inflammatory Disease
• Neurotrophic Keratitis (NK)
• Epithelial/Limbal Stem Cell Deficiency
• Others

Type

• Devices
• Medication

End User

• Hospital/Clinical Laboratories
• Physician Offices
• Reference Laboratories
• Others

Distribution Channel

• Direct Tender
• Retail Sales
• Other

North America Persistent Corneal Epithelial Defects Treatment Market Regional Analysis/Insights

The North America persistent corneal epithelial defects treatment market is analyzed and market size insights and trends are provided by clinical causes, type, end-user and distribution channel as referenced above.

The major countries covered in the North America persistent corneal epithelial defects treatment market report are the U.S., Canada, Mexico.

North America persistent corneal epithelial defects treatment market is growing due to increase in mechanical traumas cases at the significant growth rate in the forecast period of 2022 to 2029.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and North America Persistent Corneal Epithelial Defects Treatment Market Share Analysis

The North America persistent corneal epithelial defects treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to North America persistent corneal epithelial defects treatment market

Key players operating in the North America persistent corneal epithelial defects treatment market t include:

• Dompé farmaceutici S.p.A (Italy)
• Novartis AG (Switzerland)
• Abbvie,Inc (U.S.)
• Johnson & Johnson Services, Inc. (India)
• Laboratoires Théa. (France)
• Almirall, S.A (Spain)
• Ocular Science (U.S.)
• Kala Pharmaceuticals (U.S.)
• Bausch Health Companies Inc (Canada)
• Integra LifeSciences (U.S.)
• BioTissue (Florida)

SKU-51744